nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.02.2013 | Review

Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines

verfasst von: Ursula Wiedermann, Adam B. Davis, Christoph C. Zielinski

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Immunologic interventions in a subset of breast cancer patients represent a well-established therapeutic approach reflecting individualized treatment modalities. Thus, the therapeutic administration of monoclonal antibodies targeting tumor-associated antigens (TAA), such as Her-2/neu, represents a milestone in cancer treatment. However, passive antibody administration suffers from several drawbacks, including frequency and long duration of treatment. These undesirables may be avoidable in an approach based on generating active immune responses against these same targets. Only recently has the significance of tumors in relation to their microenvironments been understood as essential for creating an effective cancer vaccine. In particular, the immune system plays an important role in suppressing or promoting tumor formation and growth. Therefore, activation of appropriate triggers (such as induction of Th1 cells, CD8+ T cells, and suppression of regulatory cells in combination with generation of antibodies with anti-tumor activity) is a desirable goal. Current vaccination approaches have concentrated on therapeutic vaccines using certain TAA. Many cancer antigens, including breast cancer antigens, have been described and also given priority ranking for use as vaccine antigens by the US National Cancer Institute. One of the TAA antigens which has been thoroughly examined in numerous trials is Her-2/neu. This review will discuss delivery systems for this antigen with special focus on T and B cell peptide vaccines. Attention will be given to their advantages and limitations, as well as the use of certain adjuvants to improve anti-cancer responses.

Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6(6):229–239PubMedCrossRef

Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59(9):1295–1312PubMedCrossRef

Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18(6):884–901PubMedCrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMedCrossRef

Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28(29):4531–4538PubMedCrossRef

Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res 71(10):3505–3515PubMedCrossRef

Tan AR, Alexe G, Reiss M (2009) Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 115(3):453–495PubMedCrossRef

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949PubMedCrossRef

Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373–5380PubMedCrossRef

10.

Roepman P, Schuurman A, Delahaye LJ, Witteveen AT, Floore AN, Glas AM (2009) A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility. BMC Med Genomics 2:52PubMedCrossRef

11.

Kreike B, Hart G, Bartelink H, van de Vijver MJ (2010) Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations. Breast Cancer Res Treat 122(3):711–720PubMedCrossRef

12.

Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S et al (2009) An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 15(1):284–290PubMedCrossRef

13.

Vonka V (2012) Comments on therapeutic cancer vaccines. Immunotherapy 4(2):133–135PubMedCrossRef

14.

Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53(10):904–910PubMedCrossRef

15.

Igney FH, Krammer PH (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71(6):907–920PubMed

16.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R (2009) HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 58(5):653–664PubMedCrossRef

17.

Giorda E, Sibilio L, Martayan A, Moretti S, Venturo I, Mottolese M, Ferrara GB, Cappellacci S, Eibenschutz L, Catricala C et al (2003) The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Res 63(14):4119–4127PubMed

18.

Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R (2007) Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 25(24):3680–3687PubMedCrossRef

19.

Czerniecki BJ, Roses RE, Koski GK (2007) Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res 67(14):6531–6534PubMedCrossRef

20.

Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29(3):372–383PubMedCrossRef

21.

Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, Steinman RM (2012) Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 14(2):R39PubMedCrossRef

22.

Signori E, Iurescia S, Massi E, Fioretti D, Chiarella P, De Robertis M, Rinaldi M, Tonon G, Fazio VM (2010) DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 59(10):1583–1591PubMedCrossRef

23.

Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA (2004) Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 22(10):1916–1925PubMedCrossRef

24.

Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, Okumura S, Imai H, Shiraishi T, Masuya M et al (2006) HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 12(24):7397–7405PubMedCrossRef

25.

Kageyama S, Kitano S, Hirayama M, Nagata Y, Imai H, Shiraishi T, Akiyoshi K, Scott AM, Murphy R, Hoffman EW et al (2008) Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci 99(3):601–607PubMedCrossRef

26.

Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N et al (2012) Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. J Trans Med 10:28CrossRef

27.

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624–2632PubMedCrossRef

28.

Disis ML, Goodell V, Schiffman K, Knutson KL (2004) Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24(5):571–578PubMedCrossRef

29.

Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE (2006) Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106(11):2309–2317PubMedCrossRef

30.

Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S et al (2012) Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118(10):2594–2602PubMedCrossRef

31.

Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT (2003) A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 170(8):4242–4253PubMed

32.

Wiedermann U, Wiltschke C, Jasinska J, Kundi M, Zurbriggen R, Garner-Spitzer E, Bartsch R, Steger G, Pehamberger H, Scheiner O et al (2010) A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat 119(3):673–683PubMedCrossRef

33.

Maeda K, Hazama S, Tokuno K, Kan S, Maeda Y, Watanabe Y, Kamei R, Shindo Y, Maeda N, Yoshimura K et al (2011) Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. Anticancer Res 31(12):4569–4574PubMed

34.

Coveler AL, Goodell V, Webster DJ, Salazar LG, Fintak PA, Childs JS, Higgins DM, Disis ML (2009) Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Res Treat 113(1):95–100PubMedCrossRef

35.

Nowak AK, Lake RA, Robinson BW (2006) Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58(8):975–990PubMedCrossRef

36.

Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203(5):1259–1271PubMedCrossRef

37.

Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Lekander M, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L, Mellstedt H (2009) Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunol Immunother 58(1):111–120PubMedCrossRef

38.

Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE (2006) Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13(8):1085–1098PubMedCrossRef

39.

Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA et al (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27(28):4685–4692PubMedCrossRef

40.

Lollini PL, Cavallo F, Nanni P, Forni G (2006) Vaccines for tumour prevention. Nat Rev Cancer 6(3):204–216PubMedCrossRef

41.

Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY (2010) Strategies for cancer vaccine development. J Biomed Biotechnol 2010. doi:10.1155/2010/596432

42.

Finn OJ (2008) Cancer immunology. New Engl J Med 358(25):2704–2715PubMedCrossRef

43.

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323–5337PubMedCrossRef

44.

Yuan S, Shi C, Liu L, Han W (2010) MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy. Expert Opin Biol Ther 10(7):1037–1048PubMedCrossRef

45.

Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO (2000) Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6(5):1693–1701PubMed

46.

Curigliano G, Rescigno M, Goldhirsch A (2007) Immunology and breast cancer: therapeutic cancer vaccines. Breast 16(Suppl 2):S20–S26PubMedCrossRef

47.

Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM et al (2011) A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 17(22):7164–7173PubMedCrossRef

48.

Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH (2004) Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 53(7):633–641PubMedCrossRef

49.

Met O, Balslev E, Flyger H, Svane IM (2011) High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat 125(2):395–406PubMedCrossRef

50.

Marshall J (2003) Carcinoembryonic antigen-based vaccines. Semin Oncol 30(3 Suppl 8):30–36PubMedCrossRef

51.

Liu JP, Chen W, Schwarer AP, Li H (2010) Telomerase in cancer immunotherapy. Biochim Biophys Acta 1805(1):35–42PubMed

52.

Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Moller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G (2011) Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 60(11):1553–1564PubMedCrossRef

53.

Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE et al (2008) Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res 68(6):1636–1646PubMedCrossRef

54.

Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, Rubens RD (1996) A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 74(8):1292–1296PubMedCrossRef

55.

MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM (1996) Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19(4):309–316PubMedCrossRef

56.

Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A et al (2011) Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16(8):1092–1100PubMedCrossRef

57.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG (2008) DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther 15(1):61–64PubMedCrossRef

58.

Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R (2003) Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA 100(15):8850–8855PubMedCrossRef

59.

Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3(4):237–252PubMed

60.

Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523–1529PubMedCrossRef

61.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182PubMedCrossRef

62.

Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12(3):541–552PubMedCrossRef

63.

Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1–13PubMedCrossRef

64.

Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232(2):123–138PubMedCrossRef

65.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRef

66.

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640PubMedCrossRef

67.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30(21):2585–2592PubMedCrossRef

68.

Baselga J, Swain SM (2010) CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 10(6):489–491PubMedCrossRef

69.

Murphy CG, Morris PG (2012) Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 23(8):765–776PubMedCrossRef

70.

Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE (2011) Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev Vaccines 10(6):755–774PubMedCrossRef

71.

Curcio C, Khan AS, Amici A, Spadaro M, Quaglino E, Cavallo F, Forni G, Draghia-Akli R (2008) DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 15(2):108–114PubMedCrossRef

72.

Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R et al (2009) Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 15(5):1575–1584PubMedCrossRef

73.

Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378PubMedCrossRef

74.

Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini PL, Amici A, Di Carlo E, Musiani P, Giovarelli M et al (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 63(10):2518–2525PubMed

75.

Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY (2004) Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 111(1):86–95PubMedCrossRef

76.

Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V (2009) A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 15(3):924–932PubMedCrossRef

77.

Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R (2010) Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Trans Med 8:53CrossRef

78.

Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8(5):351–360PubMedCrossRef

79.

Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN (2010) A new era in anticancer peptide vaccines. Cancer 116(9):2071–2080PubMed

80.

Obst R, van Santen HM, Melamed R, Kamphorst AO, Benoist C, Mathis D (2007) Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proc Natl Acad Sci USA 104(39):15460–15465PubMedCrossRef

81.

Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K, Disis ML (2007) Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol 125(3):275–280PubMedCrossRef

82.

Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E et al (2008) Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26(20):3426–3433PubMedCrossRef

83.

Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE (2009) CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 9(1):71–78PubMedCrossRef

84.

Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S (2005) Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23(30):7536–7545PubMedCrossRef

85.

Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE (2011) Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 117(3):463–471PubMedCrossRef

86.

Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE (2011) Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines 10(2):201–210PubMedCrossRef

87.

Yip YL, Smith G, Koch J, Dubel S, Ward RL (2001) Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 166(8):5271–5278PubMed

88.

Garrett JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT (2007) Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 178(11):7120–7131PubMed

89.

Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E (2004) Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 173(1):394–401PubMed

90.

Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E (2005) Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu—a new method of epitope definition. Mol Immunol 42(9):1121–1124PubMedCrossRef

91.

Miyako H, Kametani Y, Katano I, Ito R, Tsuda B, Furukawa A, Saito Y, Ishikawa D, Ogino K, Sasaki S et al (2011) Antitumor effect of new HER2 peptide vaccination based on B cell epitope. Anticancer Res 31(10):3361–3368PubMed

92.

Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C, Breiteneder H, Pehamberger H, Scheiner O, Wiedermann U et al (2003) Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 107(6):976–983PubMedCrossRef

93.

Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, Zielinski CC, Wiedermann U (2007) Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 106(1):29–38PubMedCrossRef

94.

Moser C, Amacker M, Zurbriggen R (2011) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 10(4):437–446PubMedCrossRef

95.

Decker T, Fischer G, Bucke W, Bucke P, Stotz F, Gruneberger A, Gropp-Meier M, Wiedemann G, Pfeiffer C, Peschel C et al (2012) Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J Cancer Res Clin Oncol 138(11):1945–1950PubMedCrossRef

96.

Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S et al (2009) Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 15(3):1046–1051PubMedCrossRef

97.

Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, Stebbing J (2009) The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer 100(7):1061–1067PubMedCrossRef

98.

Dubensky TW Jr, Reed SG (2010) Adjuvants for cancer vaccines. Semin Immunol 22(3):155–161PubMedCrossRef

99.

Poltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Gluck R, Pluschke G (1999) Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin Exp Immunol 117(3):496–503PubMedCrossRef

100.

Ott G, Barchfeld GL, Van Nest G (1995) Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13(16):1557–1562PubMedCrossRef

101.

Garcon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M (2011) Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 25(4):217–226PubMedCrossRef

102.

Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27(2):161–167PubMedCrossRef

103.

Brichard VG, Lejeune D (2008) Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther 8(7):951–968PubMedCrossRef

104.

den Haan JM, Kraal G, Bevan MJ (2007) Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J Immunol 178(9):5429–5433

105.

Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H (2007) Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 8(12):1002–1008PubMed

106.

Sabel MS, Su G, Griffith KA, Chang AE (2010) Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat 122(2):325–336PubMedCrossRef

107.

Liu G, Yang W, Guo M, Liu X, Huang N, Li D, Jiang Z, Zhang W, Su H, Liu Z et al (2012) Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-alpha and interleukin-2. Cancer Immunol Immunother 61(12):2357–2366. doi:10.1007/s00262-012-1297-2 PubMedCrossRef

108.

Gulley JL, Madan RA, Arlen PM (2007) Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25(Suppl 2):B89–B96PubMedCrossRef

109.

Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD (2012) Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS ONE 7(2):e31962PubMedCrossRef

110.

Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC et al (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27(35):5911–5918PubMedCrossRef

111.

Bakema JE, van Egmond M (2011) Immunoglobulin A: a next generation of therapeutic antibodies? mAbs 3(4):352–361

Titel: Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
verfasst von: Ursula Wiedermann
Adam B. Davis
Christoph C. Zielinski
Publikationsdatum: 01.02.2013
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2410-8

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study

Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature

A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue

Racial differences in outcomes of triple-negative breast cancer

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer

Night-shift work and risk of breast cancer: a systematic review and meta-analysis

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie